PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: PIPELINE ANALYSIS
PART 05: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 06: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 07: MARKET SEGMENTATION BY PRODUCT
• Market segmentation by product
• Comparison by product
• Antihypertensives – Market size and forecast 2018-2023
• Anticoagulants – Market size and forecast 2018-2023
• Diuretics – Market size and forecast 2018-2023
• Anticonvulsants and others – Market size and forecast 2018-2023
• Market opportunity by product
PART 08: CUSTOMER LANDSCAPE
PART 09: MARKET SEGMENTATION BY TYPE
PART 10: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• Americas – Market size and forecast 2018-2023
• APAC – Market size and forecast 2018-2023
• EMEA – Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 11: DECISION FRAMEWORK
PART 12: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 13: MARKET TRENDS
PART 14: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 15: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Baxter
• Novartis
• Pfizer
• Sanofi
PART 16: APPENDIX
• Research methodology
• List of abbreviations
Exhibit 01: Global CNS therapeutics market
Exhibit 02: Segments of global CNS therapeutics market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Pipeline molecules for hemorrhagic stroke treatment
Exhibit 06: Market definition – Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition – Five forces 2018
Exhibit 18: Product – Market share 2018-2023 (%)
Exhibit 19: Comparison by product
Exhibit 20: Antihypertensives – Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Antihypertensives – Year-over-year growth 2019-2023 (%)
Exhibit 22: Anticoagulants – Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Anticoagulants – Year-over-year growth 2019-2023 (%)
Exhibit 24: Diuretics – Market size and forecast 2018-2023 ($ millions)
Exhibit 25: Diuretics – Year-over-year growth 2019-2023 (%)
Exhibit 26: Anticonvulsants and others – Market size and forecast 2018-2023 ($ millions)
Exhibit 27: Anticonvulsants and others – Year-over-year growth 2019-2023 (%)
Exhibit 28: Market opportunity by product
Exhibit 29: Customer landscape
Exhibit 30: Market share by geography 2018-2023 (%)
Exhibit 31: Geographic comparison
Exhibit 32: Americas – Market size and forecast 2018-2023 ($ millions)
Exhibit 33: Americas – Year-over-year growth 2019-2023 (%)
Exhibit 34: APAC – Market size and forecast 2018-2023 ($ millions)
Exhibit 35: APAC – Year-over-year growth 2019-2023 (%)
Exhibit 36: EMEA – Market size and forecast 2018-2023 ($ millions)
Exhibit 37: EMEA – Year-over-year growth 2019-2023 (%)
Exhibit 38: Key leading countries
Exhibit 39: Market opportunity
Exhibit 40: Impact of drivers and challenges
Exhibit 41: Interventions for improving drug delivery to BBB
Exhibit 42: Vendor landscape
Exhibit 43: Landscape disruption
Exhibit 44: Vendors covered
Exhibit 45: Vendor classification
Exhibit 46: Market positioning of vendors
Exhibit 47: Baxter – Vendor overview
Exhibit 48: Baxter – Business segments
Exhibit 49: Baxter – Organizational developments
Exhibit 50: Baxter – Geographic focus
Exhibit 51: Baxter – Key offerings
Exhibit 52: Novartis – Vendor overview
Exhibit 53: Novartis – Business segments
Exhibit 54: Novartis – Organizational developments
Exhibit 55: Novartis – Geographic focus
Exhibit 56: Novartis – Segment focus
Exhibit 57: Novartis – Key offerings
Exhibit 58: Pfizer – Vendor overview
Exhibit 59: Pfizer – Business segments
Exhibit 60: Pfizer – Organizational developments
Exhibit 61: Pfizer – Geographic focus
Exhibit 62: Pfizer – Segment focus
Exhibit 63: Pfizer – Key offerings
Exhibit 64: Sanofi – Vendor overview
Exhibit 65: Sanofi – Business segments
Exhibit 66: Sanofi – Organizational developments
Exhibit 67: Sanofi – Segment focus
Exhibit 68: Sanofi – Segment focus
Exhibit 69: Sanofi – Key offerings
【掲載企業】
Baxter、Novartis、Pfizer、Sanofi
【免責事項】
https://www.globalresearch.jp/disclaimer